Mini-Review| Volume 22, ISSUE 4, P197-204, August 2009

Download started.


Human Papilloma Virus Infection and Prevention in the Adolescent Population

      With the recent availability of a quadrivalent vaccine against human papillomavirus (HPV), there has been a surge of published information about this infection in both the scientific and lay press. Medical care providers desire more detailed information about HPV in order to answer the questions frequently being posed by their patients and their patient's parents or guardians. It is important to have a thorough and accurate understanding of the incidence/prevalence; risk factors for infection; pathophysiology; disease consequences of infection; updated screening guidelines for disease detection; and the latest information about HPV immunization including the Advisory Committee on Immunization Practices guidelines, efficacy in both viral-naïve and non-naïve populations, persistence of cross-neutralizing antibody levels, delayed anamnestic response to viral challenge and potential adverse events from vaccine.

      Key Words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Journal of Pediatric and Adolescent Gynecology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Weinstock H.
        • Berman S.
        • Cates Jr., W.
        Sexually transmitted diseases among American youth: incidence and prevalence estimates, 2000.
        Perspect Sex Reprod Health. 2004; 35: 6
      1. Centers for Disease Control and Prevention. MMWR Morbid Mortal Wkly Rep. 2007;56(RR-2):1-24.

        • Munoz N.
        • Bosch F.X.
        • Castellsagué X.
        • et al.
        Against which human papillomavirus types shall we vaccinate and screen? The international perspective.
        Int J Cancer. 2004; 111: 278
        • Winer R.L.
        • Lee S.K.
        • Hughes J.P.
        • et al.
        Genital human papillomavirus infection: Incidence and risk factors in a cohort of female university students.
        Am J Epidemiol. 2003; 157: 218
        • Zur Hansen H.
        • de Villiers E.M.
        • Gissmann L.
        Papillomavirus infections and human genital cancer.
        Gynecol Oncol. 1981; 2: S124
        • Schiffman M.
        • Castle P.E.
        Human papillomavirus: epidemiology and public health.
        Arch Pathol Lab Med. 2003; 127: 930
        • Parkin D.M.
        • Bray F.
        • Ferlay J.
        • et al.
        Global cancer statistics, 2002.
        CA Cancer J Clin. 2005; 55: 74
        • Bergeron C.
        • Bishop J.
        • Lemarie A.
        • et al.
        Accuracy of thin-layer cytology in patients undergoing cervical cone biopsy.
        Acta Cytol. 2001; 45: 519
        • American Cancer Society
        Cancer Facts and Figures 2007.
        American Cancer Society, Atlanta2007
        • Fitch J.T.
        • Stine C.
        • Hager W.D.
        • et al.
        Condom effectiveness: Factors that influence risk reduction.
        Sex Trans Dis. 2002; 29: 811
        • Holmes K.K.
        • Levine R.
        • Weaver M.
        Effectiveness of condoms in preventing sexually transmitted infections.
        Bull WHO. 2004; 82: 454
        • Wong E.L.
        • Roddy R.E.
        • Tucker H.
        • et al.
        Use of male condoms during and after randomized, controlled trial participation in Cameroon.
        Sex Transm Dis. 2005; 32: 300
      2. Food and Drug Administration Center for Biologics Evaluation and Research: Summary minutes, vaccines and related biological products advisory committee. Meeting #88 November 28–29, 2001, Bethesda, Maryland.

        • Block S.L.
        • Nolan T.
        • Sattler C.
        • et al.
        Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16 and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women.
        Pediatrics. 2006; 118: 2135
        • The FUTURE II Study Group
        Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions.
        N Engl J Med. 2007; 356: 1915
        • The FUTURE II Study Group
        Effect of prophylactic human papillomavirus L1 virus-like particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomized clinical trials.
        Lancet. 2007; 369: 1861
        • Garland S.M.
        • Hernandez-Avila M.
        • Wheeler C.M.
        • et al.
        • for the Females United to Unilaterally Reduce Endo/Ectocervical Disease (FUTURE) I Investigators
        Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases.
        N Engl J Med. 2007; 356: 1928
        • Joura E.A.
        • Leodolter S.
        • Hernandez-Avila M.
        • et al.
        Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulvar and vaginal lesions: a combined analysis of three randomised clinical trials.
        Lancet. 2007; 369: 1693
        • Harper D.M.
        • Franco E.I.
        • Wheeler C.M.
        • et al.
        • for the HPV Vaccine Study group
        Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial.
        Lancet. 2006; 367: 1247
        • Paavonen J.
        • Jenkins D.
        • Bosch F.X.
        • for the HPV PATRICIA study group
        Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial.
        Lancet. 2007; 369: 2161
        • Kjaer S.K.
        • Tran T.N.
        • Sparen P.
        • et al.
        The burden of genital warts: a study of nearly 70,000 women from the general female population in the 4 Nordic countries.
        J Infect Dis. 2007; 196: 1447
        • ACIP
        Recommendations for the use of quadrivalent HPV vaccine.
        (Available at) (Accessed December 3, 2007)
      3. Gee J. Vaccine Safety Datalink Project: Monitoring the Safety of Quadrivalent Human Papillomavirus Vaccine (HPV 4). Presented at Advisory Committee on Immunization Practices Meeting, October 22, 2008. Atlanta, GA.

      4. Calugar A. Quadrivalent Human Papillomavirus Vaccine (HPV 4): Post-licensure safety update, Vaccine Adverse Event Reporting System (VAERS), United States. Presented at Advisory Committee on Immunization Practices Meeting, October 22, 2008. Atlanta, GA

        • Steinbrook R.
        The potential of human papillomavirus vaccines.
        N Engl J Med. 2006; 354: 1109